2607, 2024

Exploring the Efficacy of Lurasidone as an Adjunct to Fluvoxamine in the Treatment of Obsessive-Compulsive Disorder with Comorbid Restrictive Anorexia Nervosa: A Case Report

Luglio 26th, 2024|

Abstract Introduction: Eating Disorders (EDs) significantly impact quality of life and social functioning, with varying prevalence rates and a recent rise in diagnosis due to the COVID-19 pandemic. Anorexia Nervosa (AN) frequently co-occurs with Obsessive-Compulsive Disorder (OCD), and this comorbidity [...]

2806, 2024

Optimizing and Predicting Antidepressant Efficacy in Patients with Major Depressive Disorder Using Multi-Omics Analysis and the Opade AI Prediction Tools

Giugno 28th, 2024|

Abstract According to the World Health Organization (WHO), major depressive disorder (MDD) is the fourth leading cause of disability worldwide and the second most common disease after cardiovascular events. Approximately 280 million people live with MDD, with incidence varying by [...]

705, 2024

Innova4Health: an integrated approach for prevention of recurrence and personalized treatment of Major Depressive Disorder

Maggio 7th, 2024|

Abstract Background: Major Depressive Disorder (MDD) is a prevalent mental health condition characterized by persistent low mood, cognitive and physical symptoms, anhedonia (loss of interest in activities), and suicidal ideation. The World Health Organization (WHO) predicts depression will become the leading [...]

1803, 2024

Design, Synthesis, and Pharmacological Characterization of a Potent Soluble Epoxide Hydrolase Inhibitor for the Treatment of Acute Pancreatitis

Marzo 18th, 2024|

Abstract Acute pancreatitis (AP) is a potentially life-threatening illness characterized by an exacerbated inflammatory response with limited options for pharmacological treatment. Here, we describe the rational development of a library of soluble epoxide hydrolase (sEH) inhibitors for the treatment of [...]

1803, 2024

Novel pyrrole based CB2 agonists: New insights on CB2 receptor role in regulating neurotransmitters’ tone

Marzo 18th, 2024|

Abstract The cannabinoid system is one of the most investigated neuromodulatory systems because of its involvement in multiple pathologies such as cancer, inflammation, and psychiatric diseases. Recently, the CB2 receptor has gained increased attention considering its crucial role in modulating [...]

3001, 2024

Zonulin as a Biomarker for the Development of Celiac Disease

Gennaio 30th, 2024|

Abstract Objectives: Increased intestinal permeability seems to be a key factor in the pathogenesis of autoimmune diseases, including celiac disease (CeD). However, it is unknown whether increased permeability precedes CeD onset. This study's objective was to determine whether intestinal permeability is [...]

1601, 2024

Outcomes in people with eating disorders: a transdiagnostic and disorder‐specific systematic review, meta‐analysis and multivariable meta‐regression analysis

Gennaio 16th, 2024|

Abstract Eating disorders (EDs) are known to be associated with high mortality and often chronic and severe course, but a recent comprehensive systematic review of their outcomes is currently missing. In the present systematic review and meta‐analysis, we examined cohort [...]

1812, 2023

Zonulin as a Biomarker for the Development of Celiac Disease

Dicembre 18th, 2023|

Abstract Objectives: Increased intestinal permeability seems to be a key factor in the pathogenesis of autoimmune diseases, including celiac disease (CeD). However, it is unknown whether increased permeability precedes CeD onset. This study's objective was to determine whether intestinal permeability is [...]

2411, 2023

A narrative review of digital biomarkers in the management of major depressive disorder and treatment-resistant forms

Novembre 24th, 2023|

Introduction: Depression is the leading cause of worldwide disability, until now only 3% of patients with major depressive disorder (MDD) experiences full recovery or remission. Different studies have tried to better understand MDD pathophysiology and its resistant forms (TRD), focusing on [...]

1910, 2023

Editorial: Psychometrics in psychiatry 2022: psychological therapy and psychosomatics

Ottobre 19th, 2023|

Editorial on the Research Topic Psychometrics in psychiatry 2022: psychological therapy and psychosomatics The importance of evidence-based assessment and measurement in mental healthcare has become increasingly recognized in recent decades. However, psychiatry has long grappled with challenges in quantifying subjective [...]

3008, 2023

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Agosto 30th, 2023|

Abstract Objective To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health, from observational studies and randomised controlled trials (RCTs). Design Umbrella review. Data sources PubMed, PsychInfo, Embase, up to 9 February [...]

208, 2023

Incidence, prevalence, and global burden of schizophrenia – data, with critical appraisal, from the Global Burden of Disease (GBD) 2019

Agosto 2nd, 2023|

Abstract Schizophrenia substantially contributes to the burden of mental disorders. Schizophrenia’s burden and epidemiological estimates in some countries have been published, but updated estimates of prevalence, incidence, and schizophrenia-related disability at the global level are lacking. Here, we present the [...]